Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer
By Nikita Chaurasia  Date: 2020-09-21

Innovent, Eli Lilly release results of ORIENT-11 trial for lung cancer

Innovent Biologics Inc., in collaboration with American pharmaceutical giant Eli Lilly and Company, have reportedly announced that the biomarker results of ORIENT-11 trials which were displayed during a mini verbal presentation at ESMO (European Society for Medical Oncology) Virtual Congress 2020.

As per the credible sources, ORIENT-11 is a phase 3 clinical trial that evaluates TYVYT® combined with ALIMTA® and platinum chemotherapy as a cure for recurrent or advanced nonsquamous non-small cell lung cancer without modifying ALK rearrangements or EGFR mutations.

In fact, the NMPA (National Medical Products Administration) of China has already approved the supplemental New Drug Application (sNDA) for this indication.

If sources are to be believed, data analysis on biomarker showed that MHC-II antigen presentation pathway has played a major role in immunotherapy-chemotherapy combination. Additionally, higher gene expression of this route can serve as a predictive biomarker which allows individuals to choose for whom this regimen can be beneficial.

Head of Department of Internal Medicine at Sun Yat-sen University Cancer Center as well as the primary investigator of the ORIENT-11 trials, Professor Li ZHANG, reportedly stated that there is improvement in efficiency when Sintilimab is combined with pemetrexed and platinum chemotherapy. He further added that there are no newly detected safety signals in nonsquamous metastatic or locally advanced NSCLC.

Dr. Li Wang, Senior VP at Lilly China as well as the Head of Lilly China Drug Development and Medical Affairs Center, claimed that exploring the use of biomarkers helps in effectively understanding cancer immunotherapy.  She further mentioned that the company is thrilled about the results and is looking forward to presenting the results at ESMO.

Reportedly, the primary results on the research were declared in IASLC World Conference on Lung Cancer (WCLC) 2020 Virtual Presidential Symposium in a presentation held verbally and were published by Journal of Thoracic Oncology.

Source credits-

https://www.benzinga.com/pressreleases/20/09/n17577448/innovent-and-lilly-release-biomarker-results-of-tyvyt-sintilimab-injection-in-combination-with-ali

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

LTI, IBM extend global partnership to spearhead digital transformation
LTI, IBM extend global partnership to spearhead digital transformation
By Nikita Chaurasia

The New York-headquartered IBM Corp., with its global partner Larsen Toubro Infotech, an Indian global IT solutions & services company, are planning to extend their multi-year partnership, in a bid to enable companies to revolutionize the busines...

Algae cultivator Qualitas Health raises USD 10 million in funding round
Algae cultivator Qualitas Health raises USD 10 million in funding round
By Nikita Chaurasia

In recent developments, privately held food and nutrition company Qualitas Health Inc. has reportedly secured USD 10 million in venture funds, as it looks to broaden the reach of its plant-based protein and omega-3 business. The company was appraised...

China touts plans of launching national ETS to attain carbon neutrality
China touts plans of launching national ETS to attain carbon neutrality
By Nikita Chaurasia

According to reliable sources, the Chinese government is expected to launch the much anticipated national emission trade scheme (ETS) by mid-2021 as a part of the country’s efforts of achieving carbon-neutrality by the year 2060, through market...

Fujifilm to develop large-scale cell culture manufacturing site in U.S.
Fujifilm to develop large-scale cell culture manufacturing site in U.S.
By Nikita Chaurasia

In a bid to proliferate its biopharmaceutical contract development and manufacturing business, Fujifilm Corporation is reportedly planning to invest around USD 2 billion (200 billion yen) towards the development of a large-scale cell culture manufact...

EMQ expands operations in South Korea to strengthen payment capabilities
EMQ expands operations in South Korea to strengthen payment capabilities
By Nikita Chaurasia

Hong Kong-based multinational financial settlement network EMQ Inc. has reportedly expanded its operations into South Korea to increase access to its global network ecosystem and offer more transparent as well as efficient cross-border payout capabil...